Adult Myopia Epidemiology Forecast

DelveInsight's "Adult Myopia - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Adult Myopia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Adult Myopia Understanding

The DelveInsight Adult Myopia epidemiology report gives a thorough understanding of the Adult Myopia by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Adult Myopia in the US, Europe, and Japan. The report covers the detailed information of the Adult Myopia epidemiology scenario in seven major countries (US, EU5, and Japan).

Adult Myopia Epidemiology Perspective by DelveInsight

The Adult Myopia epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Adult Myopia epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Adult Myopia epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Adult Myopia Detailed Epidemiology Segmentation

The Adult Myopia epidemiology covered in the report provides historical as well as forecasted Adult Myopia epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

 

The DelveInsight Adult Myopia report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

  • The Adult Myopia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Adult Myopia Epidemiology Report and Model provide an overview of the global trends of Adult Myopia in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight into the historical and forecasted patient pool of Adult Myopia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps recognize the growth opportunities in the 7MM for the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Adult Myopia
  • The report provides the segmentation of the Adult Myopia epidemiology

Report Highlights

  • 11-year Forecast of Adult Myopia epidemiology
  • 7MM Coverage
  • Prevalent and Diagnosed Cases of Adult Myopia
  • Cases of Adult Myopia by Mutation Types
  • Adult Myopia Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Adult Myopia?
  • What are the key findings pertaining to the Adult Myopia epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
  • What would be the total number of patients of Adult Myopia across the 7MM during the forecast period (2019-2032)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
  • What is the disease risk, burden and unmet needs of Adult Myopia?
  • What are the currently available treatments of Adult Myopia?

Reasons to buy

The Adult Myopia Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Adult Myopia market
  • Quantify patient populations in the global Adult Myopia market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Adult Myopia therapeutics in each of the markets covered
  • Understand the magnitude of Adult Myopia population by its epidemiology
  • The Adult Myopia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights 

2. Executive Summary of Adult Myopia

3. Adult Myopia: Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Adult Myopia Epidemiology Scenario in the 7MM (2019- 2032)

5.4. United States Epidemiology

5.4.1. Adult Myopia Epidemiology Scenario in the United States (2019- 2032)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Adult Myopia Epidemiology Scenario in Germany (2019- 2032)

5.5.2. France Epidemiology

5.5.2.1. Adult Myopia Epidemiology Scenario in France (2019- 2032)

5.5.3. Italy Epidemiology

5.5.3.1. Adult Myopia Epidemiology Scenario in Italy (2019- 2032)

5.5.4. Spain Epidemiology

5.5.4.1. Adult Myopia Epidemiology Scenario in Spain (2019- 2032)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Adult Myopia Epidemiology Scenario in the United Kingdom (2019-2032)

5.6. Japan Epidemiology

5.6.1. Adult Myopia Epidemiology Scenario in Japan (2019- 2032)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Adult Myopia Treatment and Management

6.2. Adult Myopia Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

*The table of contents is not exhaustive; will be provided in the final report

List of Tables

Table 1:  Adult Myopia Epidemiology in 7MM (2019-2032)

Table 2: Adult Myopia Diagnosed and Treatable Cases in 7MM (2019-2032)

Table 3: Adult Myopia Epidemiology in the United States (2019-2032)

Table 4: Adult Myopia Diagnosed and Treatable Cases in the United States (2019-2032)

Table 5: Adult Myopia Epidemiology in Germany (2019-2032)

Table 6: Adult Myopia Diagnosed and Treatable Cases in Germany (2019-2032)

Table 7: Adult Myopia Epidemiology in France (2019-2032)

Table 8: Adult Myopia Diagnosed and Treatable Cases in France (2019-2032)

Table 9: Adult Myopia Epidemiology in Italy (2019-2032)

Table 10: Adult Myopia Diagnosed and Treatable Cases in Italy (2019-2032)

Table 11: Adult Myopia Epidemiology in Spain (2019-2032)

Table 12: Adult Myopia Diagnosed and Treatable Cases in Spain (2019-2032)

Table 13: Adult Myopia Epidemiology in the United Kingdom (2019-2032)

Table 14: Adult Myopia Diagnosed and Treatable Cases in the United Kingdom (2019-2032)

Table 15: Adult Myopia Epidemiology in Japan (2019-2032)

Table 16: Adult Myopia Diagnosed and Treatable Cases in Japan (2019-2032)

List of Figures

Figure 1 Adult Myopia Epidemiology in 7MM (2019-2032)

Figure 2 Adult Myopia Diagnosed and Treatable Cases in 7MM (2019-2032)

Figure 3 Adult Myopia Epidemiology in the United States (2019-2032)

Figure 4 Adult Myopia Diagnosed and Treatable Cases in the United States (2019-2032)

Figure 5  Adult Myopia Epidemiology in Germany (2019-2032)

Figure 6  Adult Myopia Diagnosed and Treatable Cases in Germany (2019-2032)

Figure 7  Adult Myopia Epidemiology in France (2019-2032)

Figure 8 Adult Myopia Diagnosed and Treatable Cases in France (2019-2032)

Figure 9 Adult Myopia Epidemiology in Italy (2019-2032)

Figure 10 Adult Myopia Diagnosed and Treatable Cases in Italy (2019-2032)

Figure 11 Adult Myopia Epidemiology in Spain (2019-2032)

Figure 12 Adult Myopia Diagnosed and Treatable Cases in Spain (2019-2032)

Figure 13 Adult Myopia Epidemiology in the United Kingdom (2019-2032)

Figure 14 Adult Myopia Diagnosed and Treatable Cases in the United Kingdom (2019-2032)

Figure 15 Adult Myopia Epidemiology in Japan (2019-2032)

Figure 16 Adult Myopia Diagnosed and Treatable Cases in Japan (2019-2032)

*The table of contents is not exhaustive; will be provided in the final report

Forward to Friend

Need A Quote